Are you a young man who developed female breasts after taking Risperdal?
In recent months, Johnson & Johnson has lost three consecutive class action lawsuits over marketing tactics of its controversial – yet highly profitable – antipsychotic medication Risperdal (generic: risperidone). In September 2012, the company settled an individual Risperdal lawsuit filed on behalf of a young man who developed female breasts after being treated with the drug for a period of five years. If you’ve been injured by Risperdal side effects, it’s important to understand that you are not alone, and that Risperdal lawyers are now filing lawsuits in courthouses around the country.
Free Risperdal Lawsuit Evaluation: If you or a loved one has been injured by Risperdal, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.
Do you have a Risperdal Gynecomastia Lawsuit?If you’ve been injured by Risperdal side effects, it’s important to understand that you are not alone, and that Risperdal lawyers are now filing lawsuits in courthouses around the country.
Breaking News: J&J Must Pay $70M Settlement in Risperdal Gynecomastia Lawsuit
Update: Study Finds Risperdal Users 5x Likelier to Develop Gynecomastia
A new study (PDF) published in the Journal of Child and Adolescent Psychopharmacology has confirmed a link between use of Risperdal by boys and young men to the abnormal development of breast tissue, or gynecomastia. The study determined that Risperdal users were 4x more likely to develop the condition compared to non-users, and that children and adolescents who took the drug were 5x more likely to have it.
“Our study showed a strong association between risperidone use and gynecomastia in young adult males, Clinicians who are prescribing risperidone to this demographic may need to consider this adverse event in their therapeutic decision-making process,” the study’s authors concluded.
What’s the Problem?
J&J’s “Off-Label” Risperdal Marketing Plan
Plaintiffs in Risperdal lawsuits allege that Janssen Pharmaceuticals:
- Illegally marketed Risperdal to children as a treatment for autism spectrum disorders (ASDs) and other psychiatric disorders without FDA approval from 1993 to 2004;
- Actively concealed information regarding the drug’s health risks, and
- Misrepresented the potential benefits and risks of Risperdal for use in children.
2013 Risperdal Settlement
Risperdal Side Effects
- Production of prolactin
- Pituitary tumors
- Tardive Dyskinesia
- Neuroleptic Malignant Syndrome (NMS)
- Increased risk of sudden death from heart attack
- Diabetes, hyperglycemia and other blood sugar side effects
- Weight gain, potentially rapid and extreme
- Suicide, suicidal thoughts
- Bone loss
- Increased mortality in the elderly with dementia and related psychosis
- Abdominal pain
- Dry mouth
- Sore throat
- Abnormal walk
- Chest pain
- Involuntary movements
- Nasal inflammation
- Decreased activity
- Decreased sexual desires
- Lack of coordination
- Dry skin
- Difficulty urinating
- Heavy menstruation
- Weight gain
- Lethargic feelings
- Join pain
- Difficulty ejaculating
- Respiratory infection
Questions Raised About Adherence to Pediatric Antipsychotic Dosing Guidelines
J&J Settles Landmark Risperdal Gynecomastia Lawsuit on First Day of Trial
Have Risperdal Class Action Lawsuits Been Filed?
Yes. In April 2012, J&J was ordered to pay $1.1 billion over claims by the state of Arkansas that the company hid the health risks associated with Risperdal from the public and medical communities. The verdict marked the pharmaceutical giant’s third straight loss in Risperdal lawsuits filed on the state level regarding the marketing of the drug. Arkansas accused J&J of concealing the side effects of Risperdal, and of misleading the state’s Medicare program, causing it to overpay for Risperdal prescriptions.
Previous Risperdal class action lawsuits filed by the states of Louisiana and South Carolina resulted in fines against J&J of $258 million and $327 million, respectively, as well as a $158 million settlement in Texas. The U.S. Department of Justice (DOJ) has also demanded that J&J pay $1.8 billion to resolve additional complaints filed over Risperdal.